罗沙司他胶囊联合生血宝合剂对老年性血液透析患者肾性贫血的临床观察

Clinical observation of Roxastat capsule combined with Shengxuebao mixture on renal anemia in senile hemodialysis patients

目的探讨罗沙司他胶囊联合生血宝合剂对老年性血液透析患者肾性贫血的临床疗效。方法选取2020年8月至2022年1月九江市中医医院血液透析科门诊及住院部收治的60例血液透析合并肾性贫血患者作为研究对象,按照随机数字表法分为治疗组与对照组,每组30例。对照组予以重组人红细胞生成素注射液治疗,治疗组予以口服罗沙司他胶囊联合生血宝合剂治疗。比较两组临床疗效、证候积分、贫血及微炎症状态指标[血红蛋白(Hb)、红细胞压积(HCT)、红细胞(RBC)、超敏C反应蛋白(hs-CRP)]及铁代谢指标[铁调素(Hepc)、血清铁蛋白(SF)、转铁蛋白饱和度(TSAT)、转铁蛋白(Transferrin)]。结果治疗组治疗总有效率为90.00%,高于对照组的66.67%,差异有统计学意义(P<0.05)。治疗后,两组证候积分均低于治疗前,且治疗组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组Hb、HCT、RBC水平均高于治疗前,hs-CRP水平低于治疗前,且治疗组Hb、HCT、RBC、hs-CRP水平均低于对照组,差异有统计学意义(P<0.05)。治疗后,两组Hepcidin、SF、TSAT均低于治疗前,Transferrin均高于治疗前,且治疗组Hepcidin、SF、Transferrin、TSAT均低于对照组,差异有统计学意义(P<0.05)。结论罗沙司他胶囊联合生血宝合剂治疗老年性血液透析患者肾性贫血效果显著,可降低患者Hepc水平,改善肾性贫血及微炎症状态,值得临床推广应用。

Objective To investigate the clinical effect of Roxastat capsule combined with Shengxuebao mixture on renal anemia in senile hemo-dialysis patients.Methods 60 hemodialysis patients with renal anemia admitted to the outpatient department and inpatient department of the hemodi-alysis department of Jiujiang Hospital of Traditional Chinese Medicine from August 2020 to January 2022 were selected as the research subjects,and they were divided into the treatment group and the control group according to the random number table method,with 30 cases in each group.The control group was given recombinant human erythropoietin injection,and the treatment group was given oral Roxastat capsule combined with Shengxuebao mixture.The clinical efficacy,syndrome score,anemia and microinflammation indexes(hemoglobin[Hb],hematocrit[HCT],red blood cells[RBC],hypersensitive C-reactive protein[hs-CRP])and iron metabolism indexes(hepcidin[Hepc],serum ferritin[SF],transferrin saturation[TSAT],transferrin)were compared between the two groups.Results The total effective rate in the treatment group was 90.00%,which was higher than 66.67%in the control group,and the difference was statistically significant(P<0.05).After treatment,the syndrome scores of the two groups were lower than before treatment,and the treatment group was lower than the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of Hb,HCT and RBC of the two groups were higher than before treatment,and the levels of hs-CRP were lower than before treatment,and the levels of Hb,HCT,RBC and hs-CRP in the treatment group were lower than those in the control group,and the differ-ences were statistically significant(P<0.05).After treatment,Hepcidin,SF and TSAT of the two groups were lower than before treatment,and Transferrin was higher than before treatment,and Hepcidin,SF,Transferrin and TSAT in the treatment group were lower than the control group,and the differences were statistically significant(P<0.05).Conclusion Roxastat capsule combined with Shengxuebao mixture has remarkable effect in the treatment of renal anemia in senile hemodialysis patients,which can reduce the level of sideromontin and improve the status of renal anemia and microinflammation,and is worthy of clinical promotion and application.